Two-year cancer-DNA-fragment screening blood test trial to start in England to assess sensitivity and specificity of early detection of numerous cancer types. If successful, it could lead to treatment of once difficult-to-detect early cancers.

Dr. Barry Dworkin

Medical Mythbusting Commentary for September 20, 2021

Two-year Cancer DNA fragment screening blood test trial to start in England to assess sensitivity and specificity in early detection of numerous cancer types. If successful, it could lead to treatment of difficult-to-detect early cancers. Play Now | Play in Popup | Download

Source:
World’s Largest Trial Of “Game-Changer” Early Cancer Test Begins In UK

Related posts:

  1. New diagnostic, screening and disease-tracking technologies show promise
  2. Genetic test for prostate cancer recurrence can help personalize care and management
  3. Proof-of-concept blood test that screens for certain cancers shows promise
  4. Spartan Bioscience receives Health Canada approval of new SARS-Cov2 testing devices. We discuss the implications for public health policy.
Bitnami